Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 November 2023Website:
http://www.lexeotx.comNext earnings report:
11 December 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 30 Oct 2024 23:59:24 GMTDividend
Analysts recommendations
Institutional Ownership
LXEO Latest News
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that interim data from the ongoing Phase 1/2 trial (NCT03634007) of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into the central nervous systems of APOE4 homozygotes with Alzheimer's disease.
NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences: H.C.
Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline
Lexeo Therapeutics, Inc. (LXEO) could see an increase in its stock price due to increasing confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).
Analysts' price targets for Lexeo Therapeutics, Inc. (LXEO) suggest a potential 57.8% increase in the stock. Although this metric has not always been accurate, the consensus among analysts in raising earnings estimates does signal a positive outlook for the stock.
Lexeo Therapeutics, Inc. anticipates releasing results from its SUNRISE-FA study using LX-2006 for FA cardiomyopathy patients in mid-2024. Results from all cohorts of the LEAD study using LX-1001 for homozygous APOE4 AD patients are expected in the second half of 2024. The global market for Alzheimer's Disease is projected to reach $9.73 billion by 2030, with an estimated 15% to 25% of AD patients carrying this allele.
Lexeo Therapeutics (NASDAQ: LXEO ) just reported results for the third quarter of 2023. Lexeo Therapeutics reported earnings per share of -$12.36.
Lexeo Therapeutics Inc.'s stock LXEO, -15.01% tumbled 15% in its trading debut on Friday, after the company's initial public offering priced below the proposed price range. The stock priced at $11, below a $13 to $15 range.
What type of business is Lexeo Therapeutics Common Stock?
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
What sector is Lexeo Therapeutics Common Stock in?
Lexeo Therapeutics Common Stock is in the Healthcare sector
What industry is Lexeo Therapeutics Common Stock in?
Lexeo Therapeutics Common Stock is in the Biotechnology industry
What country is Lexeo Therapeutics Common Stock from?
Lexeo Therapeutics Common Stock is headquartered in United States
When did Lexeo Therapeutics Common Stock go public?
Lexeo Therapeutics Common Stock initial public offering (IPO) was on 03 November 2023
What is Lexeo Therapeutics Common Stock website?
https://www.lexeotx.com
Is Lexeo Therapeutics Common Stock in the S&P 500?
No, Lexeo Therapeutics Common Stock is not included in the S&P 500 index
Is Lexeo Therapeutics Common Stock in the NASDAQ 100?
No, Lexeo Therapeutics Common Stock is not included in the NASDAQ 100 index
Is Lexeo Therapeutics Common Stock in the Dow Jones?
No, Lexeo Therapeutics Common Stock is not included in the Dow Jones index
When was Lexeo Therapeutics Common Stock the previous earnings report?
No data
When does Lexeo Therapeutics Common Stock earnings report?
The next expected earnings date for Lexeo Therapeutics Common Stock is 11 December 2024